Nav: Home

Computer-designed vaccine elicits potent antibodies against RSV

March 07, 2019

A first-of-its-kind nanoparticle vaccine candidate for respiratory syncytial virus has been designed in an international research effort. RSV is second only to malaria as a cause of infant mortality worldwide. The new vaccine elicits potent neutralizing antibodies against RSV in both mice and monkeys. The animal research findings, reported March 7 in the journal Cell, pave the way for human clinical trials.

RSV infects nearly all children by the age of three. Infection typically causes mild symptoms, but can be more serious in newborns, immunocompromised individuals and the elderly. In the United States, RSV is the leading cause of pneumonia in babies under a year old.

According to the National Institute for Allergy and Infectious Disease, RSV is responsible for an estimated 64 million infections and causes 160,000 deaths globally each year. About 99 percent of the RSV deaths occur in developing countries. After considerable research, several vaccine candidates are in preclinical or clinical testing. As yet no RSV vaccine is ready for use in disease prevention.

"It has historically been challenging to produce an RSV vaccine that is both safe and effective, but exciting new vaccine design strategies continue to emerge," said Brooke Fiala, a research scientist at the University of Washington School of Medicine's Institute for Protein Design and a lead author of the study. "We hope to move this vaccine candidate into clinical trials soon and to continue producing vaccines for other diseases as well."

Just as a leather soccer ball is stitched from geometric patterns, the new vaccine's core is a computer-designed nanoparticle made of different parts shaped like pentagons and triangles. Each nanoparticle is more than ten million times smaller than a poppy seed. The outsides of these nanoparticles were fitted with inert RSV proteins to create the vaccine.

Those RSV proteins are prefusion-stabilized variants of the F glycoprotein trimer developed at the National Institute for Allergy and Infectious Disease Vaccine Research Center at the National Institutes of Health. That protein, known as DS-Cav1, is itself being evaluated in a Phase 1 study by NIH as an RSV vaccine candidate.

The March 7 Cell paper authors report that the nanoparticle vaccine based on DS-Cav1 was ten times more potent than DS-Cav1 alone. This finding suggests it may translate into a more effective vaccine with more durable protection.

Nanoparticles are already known to give vaccines a boost. Their use in this study is part of a larger trend called structure-based vaccine design. Recently, scientists have repurposed natural nanoparticles to create experimental vaccines for HIV, hepatitis C, and other diseases, according to a Feb. 8, 2019 Science perspective by John T. Wilson of Vanderbilt University. Using computationally designed protein nanoparticles, however, allows for much more control over important vaccine properties, such as overall size, stability, and the number of antigens presented to the immune system.

"This is the first of many vaccine candidates we have made using this technology," said senior author Neil King, assistant professor of biochemistry at the UW School of Medicine. By swapping out the proteins along the outside of the nanoparticle, King and his team hope to create new vaccines candidates for HIV, malaria, and even cancer.

"We believe that computationally designed nanoparticle vaccines will ultimately be simpler to manufacture and more effective than traditional vaccines," said King. "We will continue to develop this technology so that we and others can make new vaccines better, cheaper, and faster. We are excited to work with our many partners and collaborators to translate our work in the lab into actual vaccines that go out into the world and, hopefully, save lives."

The RSV vaccine team was led by researchers at UW Medicine and the Institute for Research in Biomedicine in Bellinzona, Switzerland. It also included scientists from Fred Hutch Cancer Research Center in Seattle, Karolinska Institute in Stockholm, Sweden; Vaccine Formulation Institute in Godalming, United Kingdom; European Virus Bioinformatics Center in Jena, Germany; the Vaccine Formulation Laboratory at the University of Lausanne, Switzerland; and the Institute of Microbiology at the Swiss Federal Institute of Technology (ETH Zu?rich), Switzerland.

Several of the Seattle researchers have launched a biotech company called Icosavax to manufacture the RSV vaccine candidate and evaluate it in clinical trials. Icosavax will also apply the nanoparticle platform to design and test vaccines for other infectious diseases.
-end-
The project was funded primarily by the Bill and Melinda Gates Foundation, and also by the state of Washington, the Howard Hughes Medical Institute, the Netherlands Organization for Scientific Research, the European Molecular Biology Organisation, the Swedish Research Council, Karolinska Institutet, National Institute of Allergy and Infectious Diseases, National Institute for General Medical Sciences, a Pew Biomedical Scholars Award, and an Investigators in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund.

University of Washington Health Sciences/UW Medicine

Related Hiv Articles:

Defective HIV proviruses reduce effective immune system response, interfere with HIV cure
A new study finds defective HIV proviruses, long thought to be harmless, produce viral proteins and distract the immune system from killing intact proviruses needed to reduce the HIV reservoir and cure HIV.
1 in 7 people living with HIV in the EU/EEA are not aware of their HIV status
Almost 30,000 newly diagnosed HIV infections were reported by the 31 European Union and European Economic Area (EU/EEA) countries in 2015, according to data published today by ECDC and the WHO Regional Office for Europe.
Smoking may shorten the lifespan of people living with HIV more than HIV itself
A new study led by researchers at Massachusetts General Hospital finds that cigarette smoking substantially reduces the lifespan of people living with HIV in the US, potentially even more than HIV itself.
For smokers with HIV, smoking may now be more harmful than HIV itself
HIV-positive individuals who smoke cigarettes may be more likely to die from smoking-related disease than the infection itself, according to a new study published in the Journal of Infectious Diseases.
Patients diagnosed late with HIV infection are more likely to transmit HIV to others
An estimated 1.2 million people live with HIV in the United States, with nearly 13 percent being unaware of their infection.
The Lancet HIV: New HIV infections stagnating at 2.5 million a year worldwide
A major new analysis from the Global Burden of Disease 2015 study, published today in The Lancet HIV journal, reveals that although deaths from HIV/AIDS have been steadily declining from a peak in 2005, 2.5 million people worldwide became newly infected with HIV in 2015, a number that hasn't changed substantially in the past 10 years.
NIH scientists discover that defective HIV DNA can encode HIV-related proteins
Investigators from the National Institutes of Health have discovered that cells from HIV-infected people whose virus is suppressed with treatment harbor defective HIV DNA that can nevertheless be transcribed into a template for producing HIV-related proteins.
Study examines risk of HIV transmission from condomless sex with virologically suppressed HIV infection
Among nearly 900 serodifferent (one partner is HIV-positive, one is HIV-negative) heterosexual and men who have sex with men couples in which the HIV-positive partner was using suppressive antiretroviral therapy and who reported condomless sex, during a median follow-up of 1.3 years per couple, there were no documented cases of within-couple HIV transmission, according to a study appearing in the July 12 issue of JAMA, an HIV/AIDS theme issue.
HIV vaccine design should adapt as HIV virus mutates
Researchers from UAB, Emory and Microsoft demonstrate that HIV has evolved to be pre-adapted to the immune response, worsening clinical outcomes in newly infected patients.
Charlie Sheen's HIV disclosure may reinvigorate awareness, prevention of HIV
Actor Charlie Sheen's public disclosure in November 2015 that he has the human immunodeficiency virus (HIV) corresponded with the greatest number of HIV-related Google searches ever recorded in the United States, according to an article published online by JAMA Internal Medicine.

Related Hiv Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#529 Do You Really Want to Find Out Who's Your Daddy?
At least some of you by now have probably spit into a tube and mailed it off to find out who your closest relatives are, where you might be from, and what terrible diseases might await you. But what exactly did you find out? And what did you give away? In this live panel at Awesome Con we bring in science writer Tina Saey to talk about all her DNA testing, and bioethicist Debra Mathews, to determine whether Tina should have done it at all. Related links: What FamilyTreeDNA sharing genetic data with police means for you Crime solvers embraced...